Hester Biosciences Ltd.

View in App
1695.00 -3.00 ▼-0.2%

03 May 2024, 04:01:00 PM
Volume: 954

Company Profile

View details >>
Sector Healthcare Sector Icon Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Industry Icon Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.hester.in
Market Cap 1,440.30 Cr.
Enterprise Value(EV) 1,693.12 Cr. 2023-09
Financial Indicators
Earnings per share (EPS) 21.71 Trailing Twelve Months Ending 2023-12
Price-Earning Ratio (PE) 77.98 Trailing Twelve Months Ending 2023-12
Industry PE 42.15 Trailing Twelve Months Ending 2023-12
Book Value / Share 334.71 Trailing Twelve Months Ending 2023-12
Price to Book Value 5.06 Calculated using Price: 1,693.10
Dividend Yield 0.47 Period Ending 2023-03
No. of Shares Subscribed 0.85 Cr. 8,506,865 Shares
FaceValue 10
About Hester Biosciences Ltd.
Hester Biosciences was incorporated on April 29, 1987 as a Private Limited Company by the name of Hester Pharmaceuticals Limited. It was subsequently converted into a Public Limited Company on November 1, 1993. The company is engaged in the manufacturing of poultry vaccines. The company has been promoted by Rajiv D. Gandhi his brother Sanjiv D. Gandhi and Dr. Bhupendra V. Gandhi. The company changed its name to the present in 2008.

Hester Biosciences Ltd. Delivery

View details >>
Delivered Qty
Traded Qty

Hester Biosciences Ltd. Performance

View details >>
1 Day
-0.18%
1 Week
+2.07%
1 Month
+12.52%
3 Month
+15.18%
6 Month
+3.31%
1 Year
-5.10%
2 Year
-35.11%
5 Year
+16.26%
10 Year
+1693.65%

Hester Biosciences Ltd. Fundamental Ratios

View details >>
9 years 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03 2022-03 2023-03
Return on Equity (%) 16.73 20.56 20.38 17.57 25.59 16.38 16.16 16.17 10.39
Return on Capital Employed (%) 17.26 18.98 19.75 20.2 26.64 16.53 17.33 14.12 9.6
Return on Assets (%) 8.84 11.08 11.43 10.1 14.97 9.04 8.7 8.11 4.55

Hester Biosciences Ltd. Balance Sheet

View details >>
Particulars 10 years 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr. 2023-09* Rs. Cr.
Shh. Funds 85 102 122 141 177 201 228 260 280 282
Non Curr. Liab. 38 41 48 44 70 97 114 198 233 260
Curr. Liab. 35 38 38 55 49 83 61 97 149 132
Minority Int. 3 5 5 4 4 5 8 7 9 10
Equity & Liab. 160 186 213 244 299 387 411 562 670 683
Non Curr. Assets 100 112 133 146 158 227 250 367 442 445
Curr. Assets 60 74 80 98 142 159 162 195 228 238
Misc. Exp. not W/O
Total Assets 160 186 213 244 299 387 411 562 670 683

Hester Biosciences Ltd. Profit and Loss

View details >>
Particulars 10 years 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr. 2023-12 Rs. Cr. TTM
Net Sales 90 101 123 136 178 183 214 235 266 293
Other Income 0 1 0 3 7 6 5 14 15 10
Total Income 90 102 124 138 185 190 219 249 281 302
Total Expenditure -65 -68 -82 -89 -110 -128 -146 -175 -216 -243
PBIDT 26 34 41 50 75 62 73 74 66 59
Interest -5 -4 -4 -4 -7 -7 -7 -4 -9 -14
Depreciation -6 -6 -7 -10 -12 -13 -13 -17 -21 -19
Taxation -5 -6 -8 -13 -16 -10 -15 -14 -12 -10
Exceptional Items 3 -3
PAT 13 19 23 23 41 31 35 39 28 16
Minority Interest 0 0 1 3 1 -2 0 0 -1 -2
Share Associate 4
Other Related Items
Consolidated Net Profit 14 19 24 26 42 29 34 39 27 18
Adjusted EPS 16 23 28 30 49 34 40 46 31 22

Hester Biosciences Ltd. Cash Flow

View details >>
Particulars 10 years 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr.
Cash Fr. Operatn. 9 20 19 35 38 47 37 58 9 24
Cash Fr. Inv. -15 -21 -13 -30 -26 -22 -74 -38 -117 -77
Cash Fr. Finan. 7 7 -7 2 -11 3 19 -18 112 42
Net Change 2 5 -1 6 1 28 -19 1 4 -12
Cash & Cash Eqvt 4 6 5 11 12 41 24 21 25 13

Hester Biosciences Ltd. Shareholding Pattern

View details >>
9 Qtrs 2022-03 (%) 2022-06 (%) 2022-09 (%) 2022-12 (%) 2023-03 (%) 2023-06 (%) 2023-09 (%) 2023-12 (%) 2024-03 (%)
Promoter 53.73 53.73 53.73 53.73 53.73 53.73 53.73 53.73 53.73
Public 46.27 46.27 46.27 46.27 46.27 46.27 46.27 46.27 46.27
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
No. of Shareholders (in Lacs)

Hester Biosciences Ltd. Announcements

View details >>
Thu, 02 May 2024
Board Meeting Intimation for Financial Results
HESTER BIOSCIENCES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/05/2024 inter alia to consider and approve the audited standalone and consolidated financial results of the Company for the quarter and year ended 31 March 2024 and to consider the declaration of dividend if any on the equity shares of the Company for the financial year 2023-24.
Wed, 01 May 2024
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of Duplicate Shares Requests under Regulation 39(3) of Listing Regulations
Wed, 10 Apr 2024
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Format of Initial Disclosure to be made by an entity identified as a Large Corporate.

Sr. No. Particulars Details
1Name of CompanyHESTER BIOSCIENCES LTD.
2CIN NO.L99999GJ1987PLC022333
3 Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr) 33.60
4Highest Credit Rating during the previous FY CAREBBB+STABLE
4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)CARE RATINGS LIMITED
5Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the frameworkBSE


We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No



Name of the Company Secretary: VINOD MALI
Designation: Company Secretary and Compliance Officer
EmailId: cs@hester.in
Name of the Chief Financial Officer: Nikhil Jhanwar
Designation: Chief Financial Officer
EmailId: cs@hester.in

Date: 10/04/2024

Note: In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.

Hester Biosciences Ltd. Technical Scans

View details >>
Fri, 03 May 2024
Opening at High Opening at High
Close Within 52 Week High Zone Close Within 52 Week High Zone
Making Higher Highs for 2 Days Making Higher Highs for 2 Days
High Increase in 3 Months High Increase in 3 Months
CCI Overbought Zone CCI Overbought Zone

Hester Biosciences Ltd. Related Stocks

View details >>
  • SALES
Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 361,915.69 1,508.40 -0.7%
Cipla Ltd. 115,033.60 1,424.40 +0.3%
Dr. Reddy's Laboratories Ltd. 105,928.76 6,332.85 +0.7%
Divi's Laboratories Ltd. 104,873.36 3,937.05 -0.7%
Zydus Lifesciences Ltd. 100,321.53 992.00 +0.4%
Mankind Pharma Ltd. 92,708.18 2,305.15 -1.2%
Torrent Pharmaceuticals Ltd. 92,483.60 2,732.60 +2.2%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-12 40.64 1,508.40 -0.7%
Cipla Ltd. Consolidated 2023-12 31.02 1,424.40 +0.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-12 20.26 6,332.85 +0.7%
Divi's Laboratories Ltd. Consolidated 2023-12 75.83 3,937.05 -0.7%
Zydus Lifesciences Ltd. Consolidated 2023-12 33.74 992.00 +0.4%
Mankind Pharma Ltd. Consolidated 2023-12 53.68 2,305.15 -1.2%
Torrent Pharmaceuticals Ltd. Consolidated 2023-12 61.90 2,732.60 +2.2%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-12 5.80 1,508.40 -0.7%
Cipla Ltd. Consolidated 2023-12 4.44 1,424.40 +0.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-12 3.94 6,332.85 +0.7%
Divi's Laboratories Ltd. Consolidated 2023-12 8.05 3,937.05 -0.7%
Zydus Lifesciences Ltd. Consolidated 2023-12 5.32 992.00 +0.4%
Mankind Pharma Ltd. Consolidated 2023-12 10.44 2,305.15 -1.2%
Torrent Pharmaceuticals Ltd. Consolidated 2023-12 12.93 2,732.60 +2.2%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 0.11 1,508.40 -0.7%
Cipla Ltd. Consolidated 2023-03 0.02 1,424.40 +0.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 0.06 6,332.85 +0.7%
Divi's Laboratories Ltd. Consolidated 2023-03 0.00 3,937.05 -0.7%
Zydus Lifesciences Ltd. Consolidated 2023-03 0.07 992.00 +0.4%
Mankind Pharma Ltd. Consolidated 2023-03 0.02 2,305.15 -1.2%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 0.85 2,732.60 +2.2%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 16.46 1,508.40 -0.7%
Cipla Ltd. Consolidated 2023-03 12.85 1,424.40 +0.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 21.36 6,332.85 +0.7%
Divi's Laboratories Ltd. Consolidated 2023-03 14.89 3,937.05 -0.7%
Zydus Lifesciences Ltd. Consolidated 2023-03 11.60 992.00 +0.4%
Mankind Pharma Ltd. Consolidated 2023-03 19.27 2,305.15 -1.2%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 20.50 2,732.60 +2.2%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 16.46 1,508.40 -0.7%
Cipla Ltd. Consolidated 2023-03 12.85 1,424.40 +0.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 21.36 6,332.85 +0.7%
Divi's Laboratories Ltd. Consolidated 2023-03 14.89 3,937.05 -0.7%
Zydus Lifesciences Ltd. Consolidated 2023-03 11.60 992.00 +0.4%
Mankind Pharma Ltd. Consolidated 2023-03 19.27 2,305.15 -1.2%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 20.50 2,732.60 +2.2%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 43,885.68 1,508.40 -0.7%
Cipla Ltd. Consolidated 2023-03 22,753.12 1,424.40 +0.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 24,669.70 6,332.85 +0.7%
Divi's Laboratories Ltd. Consolidated 2023-03 7,767.51 3,937.05 -0.7%
Zydus Lifesciences Ltd. Consolidated 2023-03 17,237.40 992.00 +0.4%
Mankind Pharma Ltd. Consolidated 2023-03 8,749.43 2,305.15 -1.2%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 9,620.15 2,732.60 +2.2%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 8,560.84 1,508.40 -0.7%
Cipla Ltd. Consolidated 2023-03 2,835.49 1,424.40 +0.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 4,507.30 6,332.85 +0.7%
Divi's Laboratories Ltd. Consolidated 2023-03 1,823.38 3,937.05 -0.7%
Zydus Lifesciences Ltd. Consolidated 2023-03 2,001.90 992.00 +0.4%
Mankind Pharma Ltd. Consolidated 2023-03 1,309.68 2,305.15 -1.2%
Torrent Pharmaceuticals Ltd. Consolidated 2023-03 1,245.23 2,732.60 +2.2%

Hester Biosciences Ltd. FAQ's

What is Hester Biosciences share price?
Can I buy Hester Biosciences shares now?
What is the Dividend Yield of Hester Biosciences?
What is the Market Cap of Hester Biosciences?
What are the key metrics to analyse Hester Biosciences?
What is the 52 Week High and Low of Hester Biosciences?
What is the trend of Hester Biosciences share price?